Moleculin Biotech, INC S-1 registration statements

Moleculin Biotech announces a public offering of up to 4,566,210 shares of common stock and accompanying warrants, aiming to raise approximately $9.1 million for clinical development.

Moleculin Biotech, Inc. has filed a Form S-1 registration statement to offer shares of common stock, pre-funded warrants, and common warrants to the public.

Moleculin Biotech, Inc. is seeking to raise up to $6.8 million through a 'reasonable best efforts' public offering of common stock and warrants, as the company faces Nasdaq non-compliance and a critical need for near-term capital to fund its drug development programs.

Moleculin Biotech, Inc. is conducting a 'reasonable best efforts' public offering of common stock and Series E warrants to fund its clinical development, particularly its lead drug Annamycin for AML, while simultaneously facing a Nasdaq non-compliance notice regarding its stockholders' equity.

Moleculin Biotech, Inc. has initiated a 'reasonable best efforts' public offering of common stock and warrants to raise up to $7.5 million, while simultaneously addressing a Nasdaq non-compliance notice regarding its stockholders' equity.

Moleculin Biotech, Inc. has initiated a 'reasonable best efforts' public offering of up to $10 million in common stock and warrants to fund clinical development, while simultaneously addressing a Nasdaq non-compliance notice regarding its minimum stockholders' equity.

Moleculin Biotech has filed a registration statement for the resale of up to 18,199,198 shares of its common stock by a selling stockholder, which are issuable upon the exercise of outstanding warrants.

Moleculin Biotech is seeking to raise up to $20 million through a public offering of common stock and warrants to fund clinical development and research.

Moleculin Biotech is planning to offer shares of common stock, pre-funded warrants, and common warrants in a best efforts offering to raise up to $20 million.

Moleculin Biotech is launching a public offering of common stock and warrants to raise up to $8 million for clinical development of its cancer and antiviral drug portfolio.

Moleculin Biotech is launching a public offering to raise up to $8 million to fund the clinical development of its cancer drug candidates, including Annamycin.

Moleculin Biotech is seeking to raise up to $7 million through a public offering of common stock and warrants to fund the clinical development of its cancer drug candidates.

Moleculin Biotech is offering up to 2,978,723 shares of common stock along with warrants in a best efforts offering to fund clinical development of its cancer and antiviral drug portfolios.

Moleculin Biotech is offering up to 3,409,091 shares of common stock along with accompanying warrants in a best efforts offering, aiming to raise capital for clinical development and research.

Moleculin Biotech is launching a best efforts public offering of common stock and warrants, aiming to raise up to $12 million to fund clinical development and research.

Moleculin Biotech is registering for resale up to 14,089,672 shares of its common stock issuable upon the exercise of outstanding warrants.